{"podcast":{"title":"BioSpace","slug":"biospace-6696251","podcast_index_feed_id":6696251,"rss_url":"https://api.riverside.fm/hosting/3SxyDAXU.rss","website_url":"https://www.biospace.com/","image_url":"https://hosting-media.riverside.com/media/imports/podcasts/a2a52916-bfe1-4f2a-b9a3-9be5029ecbe4/39510587-1699400129885-1e919ae7cb2aa.jpg","author":"BioSpace","episode_count":247,"summary":"Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.","last_synced_at":"2026-07-15T16:19:04.105662+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251"},"episode":{"title":"Portugal, Spain and the new biotech frontier","slug":"portugal-spain-and-the-new-biotech-frontier","published_at":"2026-06-10T23:00:00+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251/portugal-spain-and-the-new-biotech-frontier","show_page_url":"https://stenobird.com/podcast/biospace-6696251","url":"https://api.riverside.com/hosting-analytics/media/c63bb6b2a2bfbcf3869341a8dcb2b9cbdf89f41bcc599ba8959d0fee66032b7b/eyJlcGlzb2RlSWQiOiJhNjU0NGQ5NS1iNjIxLTRmMTAtOGQ3Ny0xZjFhMjNlNDYwZmMiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEyOTc1YzNmMjcwMjk3MzFjOTFmNTMxL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTEwX18xNi0zMy0zOS5tcDMifQ==.mp3","audio_url":"https://api.riverside.com/hosting-analytics/media/c63bb6b2a2bfbcf3869341a8dcb2b9cbdf89f41bcc599ba8959d0fee66032b7b/eyJlcGlzb2RlSWQiOiJhNjU0NGQ5NS1iNjIxLTRmMTAtOGQ3Ny0xZjFhMjNlNDYwZmMiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEyOTc1YzNmMjcwMjk3MzFjOTFmNTMxL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTEwX18xNi0zMy0zOS5tcDMifQ==.mp3","summary":"In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll hear from Hannah Franklin, associate at Biovance Capital and Pablo Gabriel Cironi Lopez, director of life science investment at Caixa Capital Risc. We examine the rise of Southern Europe’s biotech ecosystem—from Portugal’s efforts to turn strong science into startups to Spain’s growing depth of capital and talent—and what it will take for the region to compete globally. Host ⁠Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Hannah Franklin , Associate, Biovance Capital Pablo Gabriel Cironi Lopez , Director, Life Science Investment, Caixa Capital Risc Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.","meta_description":"In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll hear from Hannah Franklin, associate at Bio…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1233,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/portugal-spain-and-the-new-biotech-frontier/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/biospace-6696251/portugal-spain-and-the-new-biotech-frontier.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}